CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Cannabisdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01798186
NCT01798186Phase 1Completed
CompareCT.gov

Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation

Johns Hopkins University·interventional·Posted Feb 25, 2013·Updated Aug 3, 2017

In Brief

A Phase 1 clinical trial evaluating Cannabis for Cannabis Toxicology. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This primary aim of this study is to assess the effects of passive (second-hand) inhalation of cannabis smoke on toxicological analysis of "native" oral fluid (saliva), urine and blood specimens. The results of this study will help inform the validity of oral fluid as a biomarker of cannabis exposure and to determine whether, and for how long, passive inhalation of cannabis smoke could result in a positive toxicology result.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Toxicology
CountriesUnited States
CollaboratorsSubstance Abuse and Mental Health Services Administration (SAMHSA), RTI International

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 25, 2013
Enrollment StartMay 1, 2013
Primary CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 13.4 years ago

Interventions

Cannabisdrug

Participants will be exposed to cannabis smoke present in ambient air